Is Gland Pharma the Best Stock in Its Sector? A Look at the Numbers

Gland Pharma CMP Rs 2,905 (15 Sep 2026). Market cap Rs 48,215 Cr. ROE 9.92%. P/E 42.71x versus Industry P/E 37.96x.

Updated: 15 Sept 2026 • 2:18 pm

Posted by:

Is Gland Pharma the Best Stock in Its Sector? A Look at the Numbers

Quick Answer

Gland Pharma is one of the names investors compare when screening the Healthcare sector, built on a 9.92% return on equity and a P/E of 42.71x against an Industry P/E of 37.96x. Gland Pharma Ltd manufactures complex injectable formulations and provides contract development and manufacturing (CDMO) services to pharmaceutical companies globally, with a majority stake held by China’s Fosun Pharma. Whether Gland Pharma is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.

Is Gland Pharma the best stock in its sector? The stock trades on the NSE at Rs 2,905 as of 15 September 2026, within its 52-week range of Rs 1,573.60 to Rs 3,042.00. Gland Pharma Ltd manufactures complex injectable formulations and provides contract development and manufacturing (CDMO) services to pharmaceutical companies globally, with a majority stake held by China’s Fosun Pharma.

Gland Pharma sits in the Healthcare sector, and its 9.92% ROE and 42.71x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

Table of Contents

About Gland Pharma

Gland Pharma Ltd manufactures complex injectable formulations and provides contract development and manufacturing (CDMO) services to pharmaceutical companies globally, with a majority stake held by China’s Fosun Pharma. At a market capitalisation of Rs 48,215 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Gland Pharma the Best Stock in Its Sector?

Gland Pharma makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 9.92% ROE with a 42.71x P/E against the sector’s 37.96x Industry P/E. Gland Pharma’s 42.71x P/E is close to the 37.96x Industry P/E, though its 9.92% ROE trails both Global Health and the MNC pharma peers used elsewhere in this series.

Metric	Gland Pharma
CMP (NSE)	Rs 2,905.00
52-Week High / Low	Rs 3,042.00 / Rs 1,573.60
Market Cap	Rs 48,215 Cr
P/E (TTM) vs Industry P/E	42.71x vs 37.96x
P/B	4.65
ROE	9.92%
EPS (TTM)	Rs 68.43
Dividend Yield	0.68%
Debt to Equity	0.03

Compare Gland Pharma Against Other Healthcare Sector Stocks

How Gland Pharma Compares Against Its Healthcare Sector Peers

The table below sets Gland Pharma against 3 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 3 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Gland Pharma	48,215	42.71	9.92%	0.03
Global Health	38,921	70.47	14.05%	0.30
Pfizer	18,583	25.28	17.19%	0.02
Sanofi India	7,093	21.91	39.20%	0.02
Peer average (3 companies)	–	39.22	23.48%	0.11

Against this peer set, Gland Pharma’s 9.92% ROE is below the 23.48% peer average, and its P/E of 42.71x runs above the peer average of 39.22x. Gland Pharma’s 42.71x P/E is close to the 37.96x Industry P/E, though its 9.92% ROE trails both Global Health and the MNC pharma peers used elsewhere in this series.

What Makes Gland Pharma Worth Watching in Healthcare

Near debt free balance sheet: A debt to equity ratio of 0.03 gives Gland Pharma flexibility to invest in new manufacturing capacity.
Specialised injectables and CDMO focus: Concentrating on complex injectables and contract manufacturing differentiates Gland Pharma from generic oral-solid formulation makers.
Slight premium to Industry P/E: A 42.71x P/E against a 37.96x Industry P/E is a modest premium for its specialised manufacturing capability.

Gland Pharma Valuation: Is It Justified?

Gland Pharma’s 42.71x P/E is close to the 37.96x Industry P/E, though its 9.92% ROE trails both Global Health and the MNC pharma peers used elsewhere in this series. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Bata India the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Gland Pharma and other Healthcare sector stocks.

How to Track Gland Pharma Before You Invest

Before deciding whether Gland Pharma deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

Open the Univest Screener and search for Gland Pharma to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Gland Pharma earns a place in the best stock in its sector conversation on the strength of a 9.92% ROE and a P/E of 42.71x against a 37.96x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Is Gland Pharma the best stock in its sector?

Ans. Gland Pharma has a 9.92% ROE and trades at 42.71x P/E against a 37.96x Industry P/E, and compares below the peer average ROE of 23.48% in this article’s named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Gland Pharma?

Ans. Gland Pharma was trading at Rs 2,905.00 on the NSE as of 15 September 2026, within its 52-week range of Rs 1,573.60 to Rs 3,042.00.

What sector does Gland Pharma belong to?

Ans. Gland Pharma is classified under the Healthcare sector on Univest.

How does Gland Pharma compare to its sector peers on P/E?

Ans. Gland Pharma’s P/E of 42.71x is above the 39.22x average of the 3 named peers compared in this article.

What is Gland Pharma’s return on equity?

Ans. Gland Pharma reported a return on equity of 9.92%, which is below the 23.48% average of its named peers in this comparison.

Should I invest in Gland Pharma based on its sector position?

Ans. Gland Pharma’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.